Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724540 · ClinicalTrials.gov registry record · Phase 2
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT02724540: Completed Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02724540 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 162 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02724540, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.
Primary Outcome
Hepatic progression-free interval (H-PFS)
Interventions
- COMBINATION_PRODUCT Transarterial chemoembolization
- DEVICE Bland Embolization
- COMBINATION_PRODUCT Drug Eluting Beads Embolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2016-03 |
| Est. Completion | 2024-11-08 |
| Phase | Phase 2 |
What the finished NCT02724540 record still lists
NCT02724540 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 3 interventions - of which Transarterial chemoembolization is the first listed.
NCT02724540 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02724540 about?
NCT02724540 is a clinical study titled "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver". The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembo...
What is the current status of trial NCT02724540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2016-03. Estimated completion is 2024-11-08.
What interventions are being tested in trial NCT02724540?
The interventions under investigation include: Transarterial chemoembolization (COMBINATION_PRODUCT), Bland Embolization (DEVICE), Drug Eluting Beads Embolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02724540?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02724540's enrollment target sits among peer trials
162 418th of 2000 higher than 1,579 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia